Clinical trials: Recurrence
Lymphoma, Hodgkin's Disease
Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
Patients have a type of lymph gland cancer called HD, NHL or lymphoepithelioma (these 3 diseases will be referred to as "Lymphoma"). The lymphoma has come back or has not gone away after treatment.
- Conditions
- Lymphoma, Hodgkin's Disease, Relapse, Lymphoma, Non-Hodgkin
- Trial name
- TGF-beta (NCT00368082)
- Testing
- TGFbeta resistant LMP-specific CTLs
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Baylor College of Medicine
Lymphoma
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK.
- Trial name
- NCT02974647
- Testing
- Ruxolitinib
- Where
- 10 sites in United States
- Volunteers
- 83 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
- Trial name
- NCT03618550
- Testing
- pembrolizumab, gemcitabine, vinorelbine
- Where
- 10 sites in United States
- Volunteers
- 257 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed…
- Trial name
- GBM AGILE (NCT03970447)
- Testing
- Temozolomide, Lomustine, Regorafenib
- Where
- 63 sites in United States, Australia and 4 more
- Volunteers
- 2,250 people
- Sponsor
- Global Coalition for Adaptive Research
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
Background: Chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) are diseases in which the body makes too many white blood cells that do not work properly.
- Trial name
- NCT07796373
- Testing
- Nemtabrutinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
NHL, NHL, Relapsed, Adult
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
- Trial name
- NCT05879744
- Testing
- CLN-978
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Cullinan Therapeutics Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not…
- Trial name
- NCT06769698
- Testing
- FDC fianlimab+cemiplimab, Cemiplimab
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Lymphoma, B-cell Lymphomas
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
The goal of this clinical trial is to assess the clinical efficacy of bridging therapy with glofitamab/gemcitabine/oxaliplatin (Glofit-GemOx) followed by lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell…
- Conditions
- Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- GLORY (NCT07711483)
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Massachusetts General Hospital
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study
This is a Phase I/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic…
- Trial name
- CARLLA-B1 (NCT07890025)
- Testing
- MB-CART19.1
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Lymphoma, Relapsed
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma.
- Conditions
- Lymphoma, Relapsed, Refractory
- Trial name
- NCT03179930
- Testing
- Entinostat, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Primary Central Nervous System Lymphoma, Recurrent Cancer
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL).
- Conditions
- Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
- Trial name
- NCT04421560
- Testing
- Ibrutinib, Pembrolizumab, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed/Refractory B-cell Malignancies
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
- Trial name
- NCT06590961
- Testing
- UBX-303061
- Where
- 11 sites in United States, Poland and 1 more
- Volunteers
- 94 people
- Sponsor
- Ubix Therapeutics, Inc.
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- NCT07104721
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07123519
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Colon Polyp, Adenoma
Six Versus Twelve Month Index Follow-up After Large Colon Polyp Resection
The study will compare the use of a 6-month follow-up vs a 12-month follow-up after the removal of a large non-pedunculated polyp 20-50mm in size and without high grade dysplasia.
- Conditions
- Colon Polyp, Adenoma, Serrated Polyp, Recurrence, Local Neoplasm
- Trial name
- STARLING (NCT07198945)
- Testing
- 6-month follow-up, 12-month follow-up
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 546 people
- Sponsor
- Indiana University
Moderate Acute Malnutrition (MAM), Undernutrition
Effectiveness of Positive Deviance/Hearth in Treating Uncomplicated Moderate Acute Malnutrition in Children 6-59 Months in Mymensingh Division, Bangladesh
The goal of this clinical trial (cluster randomized controlled trial) is to learn whether a Positive Deviance/Hearth (PDH) intervention can effectively treat moderate acute malnutrition (MAM) and reduce relapse compared to…
- Conditions
- Moderate Acute Malnutrition (MAM), Undernutrition, Wasting
- Trial name
- PD/Hearth MAM (NCT07591064)
- Testing
- PD/Hearth is a behavioral change program that teaches caregivers how to cook and feed their children. A nutrient-dense meal using local ingredients will be fed to children during Hearth sessions., Standard of Care (Investigator Selected)
- Where
- Bangladesh
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- World Vision US
Advanced Solid Tumors, Recurrent or Progressive Glioblastoma
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
This is a Phase 1, open-label, dose-escalation study of CBX-663 in participants with R/R AML, MDS or CMML (Cohort A), advanced solid tumors (Cohort B), or recurrent or progressive GBM (Cohort C) (collectively called 'indication…
- Conditions
- Advanced Solid Tumors, Recurrent or Progressive Glioblastoma, Relapse or Refractory Myeloid Malignancies
- Trial name
- TelOscope (NCT07779798)
- Testing
- CBX-663
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Crossbow Therapeutics, Inc.
Brain Metastases, Radiation Necrosis
REMASTer: REcurrent Brain Metastases After SRS Trial
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic…
- Conditions
- Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
- Trial name
- NCT05124912
- Testing
- Radiation Therapy, Steroid Therapy, Laser Interstitial Thermal Therapy
- Where
- 9 sites in United States
- Volunteers
- 261 people
- Sponsor
- Monteris Medical
Relapsed/Refractory Primary Central Nervous System Lymphoma
IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous…
- Trial name
- IGNITE (NCT07104032)
- Testing
- Tirabrutinib, Rituximab, Temozolomide
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 132 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Recurrent Pericarditis, Heart Diseases
Transition to KPL-387 Monotherapy Dosing & Administration Study
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent…
- Conditions
- Recurrent Pericarditis, Heart Diseases, Pericarditis
- Trial name
- NCT07288216
- Testing
- KPL-387
- Where
- 47 sites in United States, Canada and 8 more
- Volunteers
- 120 people
- Sponsor
- Kiniksa Pharmaceuticals International, plc